Table 1. Characteristics of included studies.
| First Author, Year |
Total
Patients, N |
Stage | Age Median or Mean (Range) | Follow up Time | Nilutamide Dose | Comparator | Efficacy Population |
|---|---|---|---|---|---|---|---|
| Beland 1990 [9] | 194 | stage D2 | 69 (42-93) | Up to 48 months and for a minimum of 18 months |
100 mg TID† | Placebo | NR* |
| Beland 1991 [10] | 174 | stage D2 | NR | NR | 100 mg TID | Placebo | NR |
| Dijkman 1997 [7] | 457 | stage D2 | NR | 8.5 years | 300 mg for 1 month and then 150 mg OD‡ | Placebo | ITT§ |
| Janknegt 1993 (1) [11] | 457 | stage (M+) | NR | 5 years | 300 mg for 1 month and then 150 mg OD | Placebo | ITT |
| Janknegt 1993 (2) [12] | 423 | stage (M+) | 71 (46-86) | 35 month | 300 mg for 1 month and then 150 mg OD | Placebo | ITT |
| Namer 1990 [13] | 150 | Stage D1 and D2 | NR | NR | 300 mg | Placebo | NR |
*NR: Not reported; †TID: Three times a day; ‡OD: Once a day; §ITT: Intent to treat.